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Name 
	Timothy M. Wick 	 X Active 	  Pending 	  None 
The 	Whitaker Foundation 	7.M. Wick a. Source and identifying no. 	 P I 
Title Endothelial Cell Activation and Blood Cell Adhesion in Atherosclerosis 
 
Principal Investigator 	 25% b. Your role on project 	  % Effort 
c. Dates and costs of entire project 	1 July 1991 — 30 June 1994 	($179,999) 
d. Dates and costs of current year 	1 July 1992 - 30 June 1993 	($48,444 direct) 
e. Specific aims of project 	To elucidate the mechanism of adherence of monocytes to endothelial 
cells under physiologically relevant conditions. 
f. Describe scientific and budgetary overlap No scientific or budgetary overlap. 
 
g. Describe adjustments you will make if the present application is funded (budget, % effort, aims, etc.) 
None. 































Principal Investigator/Program Director (Last, first, middle):  Wick, Timothy M. 	(HL44960-03)  
Timothy M. Wick 	 Active (continued) 
2. 
a. Source and Identifying Number: NIH 1-P01-HL48482-01 
P.I. James R. Eckman, M.D., Associate Professor of Medicine in Hematology/Oncology, Assistant 
Professor of Pediatrics in Human Genetics, Emory University School of Medicine, Atlanta, Georgia. 
Title: Georgia Comprehensive Sickle Cell Center 
b. Your role on project: Collaborating Investigator 	 % Effort: 30% 
c. Dates and costs of entire project: 1 April 1993 - 31 March 1998 $5,085,570 (direct) 
d. Dates and costs current year: 1 April 1993 - 31 March 1994 $867,809 (direct) 
e. Specific aims of project: The primary goal of the Georgia Comprehensive Sickle Center is to 
provide basic and clinical research, education, laboratory diagnosis, counseling and patient care in 
sickle cell syndromes. Research projects will address issues of pathophysiology and treatment for 
important complications in patients with these disorders. Dr. Wick's role in the Center is to develop 
and execute investigations into the effects of sickle red blood cells on endothelial cell morphology and 
function. These important studies will provide insight into the mechanism of sickle red cell induced 
endothelial cell damage and the related clinical complications (such as stroke), not necessarily related 
to microvascular occlusion. We are testing the hypothesis that sickle erythrocytes alter endothelial cell 
morphology, metabolic processes, and function. Specifically, we have data that sickle red blood cells 
inhibit endothelial cell responses to arterial levels of shear stress, sickle cells induce endothelial cell 
adhesion molecule expression, and stimulation of endothelial cells with sickle red cells increases the 
affinity of the endothelium for sickle erythrocytes. The SCORE research that involves Dr. Wick is 
complementary to the erythrocyte adherence studies related to microvascular occlusion ongoing under 
the current R29 award. 
f. Describe budgetary and scientific overlap: The budgetary overlap is limited to the PI's salary. 
g. Describe adjustments you will make if the present application is funded (budget, % effort, 
aims, etc.): The PI's salary on this project will be reduced from 50% to 20%. This reduction 
eliminates the funding overlap between the R29 and Dr. Wick's funding from the SCORE which arose 
because the projects are complementary, and some of Dr. Wick's efforts benefit both projects 
simultaneously. For example, study design, sample collection, data analysis, research group meetings 
with collaborators, report writing, etc. for the projects are interrelated and Dr. Wick, as PI, actively 
participates in each of these areas. In addition, Dr. Wick is heavily involved in the design and 
execution of experiments related to both projects. The 20% effort on the R29 and the 30% effort on 
the SCORE and the related revised budgets accurately reflect Dr. Wick's commitment to and 
participation in both projects. Note that with these budget revisions, Dr. Wick still devotes 50% effort 
to his studies in the area of sickle cell/endothelial adherence and the related effects of sickle cells on 
endothelial cell biology. With this revision, the PI's salary and fringe benefits have been reduced by 
$20,670 in the R29 for years 3-5. 
The aims will be adjusted slightly as indicated in the report (see Plans). This adjustment is made 
solely on the basis of our results to date as reported. We will focus our efforts on identifying the 
adherence mechanism(s) utilized when sickle cells are suspended in autologous plasma. This emphasis 
is based on the knowledge that plasma is the milieu in vivo. and our belief that integrin receptors 
account for a significant fraction of the plasma-mediated adherence. We are interested in 
investigating anti-integrin receptor peptides for their ability to inhibit or reverse adherence in a plasma 
environment in order to provide data of use in the development of anti-adhesion therapies. 
With this budget adjustment, NIH will be funding 1 graduate student and Dr. Wick for 20% effort on 
the R29 and 2 graduate students and Dr. Wick for 30% effort on the SCORE research. Clearly our 
preliminary data as detailed in the proposals justify this level of funding for sickle cell/endothelial cell 
interactions. 
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Principal Investigator/Program Director (Last, first, middle):  Wick, Timothy M. 	(1-14 4 9 60-0 3)  
3. 
a. Source and Identifying Number: NIH 1T32GM08433-02 	P.I. Robert M. Nerem, Ph.D. 
Title: Cellular Engineering Training Program 
b. Your role on project: Collaborating Faculty 	 % Effort: 5% 
c. Dates and costs of entire project: $339,208 (26 September 1991 - 31 August 1995) 
3 	d. Dates and costs current year: $59,460 (1 July 1992 - 30 June 1993) 
Li 
e. Specific aims of project: This project provides funds for predoctoral students studying Cellular 
Engineering. 
f. Describe budgetary and scientific overlap: None. 
g. Describe adjustments you will make if the present application is funded (budget, % effort, 
aims, etc.): None. 
- 4. 
Source and Identifying Number: The Whitaker Foundation 	P.I. Robert M. Nerem, Ph.D. 
Title: Biomedical Engineering Education: An Interdisciplinary Tissue Engineering Education and 
▪ Research Program 
b. Your role on project: Participating faculty 	 % Effort: 0% 
c. Dates and costs of entire project: $3,000,000 (1 September 1993 - 31 August 1996) 
▪ d. Dates and costs current year: $1,500,000 (1 September 1993 - 31 August 1994) 
e. Specific aims of project: This grant provides funds for laboratory space renovation, the hiring of six 
new faculty in Tissue Engineering, and a limited number of graduate student stipends. 
• 1.  Describe budgetary and scientific overlap: None. 
g. Describe adjustments you will make if the present application is funded (budget, % effort, 
aims, etc.): None. 
PENDING  
None. 
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Source and Identifying Number: NSF BCS9111761 	 P.I. Robert M. Nerem, Ph.D. 
Title: Reconstitution of a blood vessel in culture 
b. Your role on project: Co-investigator 	 % Effort: 5% 
c. Dates and costs of entire project: $443,740 (1 September 1991 - 28 February 1995) 
d. Dates and costs current year: $178,461 (1 September 1992 - 31 August 1993)> ($10,000 annual 
direct costs for Dr. Wick) 
e. Specific aims of project: Dr. Wick will evaluate the thrombogenicity of tissue engineered blood 
vessels developed in Dr. Nerem's lab. 
f. Describe budgetary and scientific overlap: None. 
g. Describe adjustments you will make if the present application is funded (budget, % effort, 
aims, etc.): None. 
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FOLLOW INSTRUCTIONS CAREFULLY. Incomplete, inaccurate, or ambiguous information about OTHER SUPPORT could lead to 
significant delays in the review and/or funding of the application. 
Other support is defined as all funds or resources, whether Federal, non-Federal, or institutional, available to the principal 
investigator/program director (and other key personnel named in the application) in direct support of their research endeavors through 
research or training grants, cooperative agreements, contracts, fellowships, gifts, prizes, and other means. 
Reporting requirements are: For each of the key personnel, describe (1) all currently active support and (2) all applications and proposals 
pending review or award, whether related to this application or not. If the support is part of a larger project, identify the principal 
investigator/program director and provide the data for the relevant subproject(s). If an individual has no active or pending support, check 
"None." Use continuation pages as needed to provide the required information in the format as shown below. Key personnel are 
defined as all individuals who participate in the scientific development or execution of the project. Key personnel typically will include 
all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or baccalaureate 
level provided they contribute in a substantive way to the scientific development or execution of the project. 
Name 	James R. Eckman 	Active 	X 	Pending 	  None 	  
a. Source and identifying no. 	NIH/NHLBI, 1 P60 HL48482-01 	P I. James Eckman 
Title 	Georgia Comprehensive Sickle Cell Center 
b. Your role on project Principal Investigator 	% Effort 	32% 
  
c. Dates and costs of entire project 	4/1/93 - 3/31/98: $8,299,001  
d. Dates and costs of current year 4/1/93 - 3/31/94: $1,237,856 
 
e. Specific aims of project The primary goal of the grant is to provide basic and clinical research,  education, 
 
laboratory diagnosis, counseling and patient care in sickle cell syndromes. Research projects will address issues 
of pathophysiology and treatment for important complications in patients with these disorders. 
f. Describe scientific and budgetary overlap 	None.  
g. Describe adjustments you will make if the present application is funded (budget, °A, effort, aims, etc.) 
None. 
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significant delays in the review and/or funding of the application. 
Other support is defined as all funds or resources, whether Federal, non•Federal, or institutional, available to the principal 
investigator/program director (and other key personnel named in the application) in direct support of their research endeavors through 
research or training grants, cooperative agreements, contracts, fellowships, gifts, prizes, and other means. 
Reporting requirements are: For each of the key personnel, describe (1) all currently active support and (2) all applications and proposals 
pending review or award, whether related to this application or not. If the support is part of a larger project, identify the principal 
investigator/program director and provide the data for the relevant subproject(s). If an individual has no active or pending support, check 
"None." Use continuation pages as needed to provide the required information in the format as shown below. Key personnel are 
defined as all individuals who participate in the scientific development or execution of the project. Key personnel typically will include 
all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or baccalaureate 
level provided they contribute in a substantive way to the scientific development or execution of the project. 
Active Name 	Jampc R Frkmart 	 X 	Pending 	  None 	  
Fulton-Dekalb 
a Source and identifying no. 	Georgia D.H.R., 93-50288 	p I 	Hosp. Authority  
Title 	Treatment of Sickle Cell Anemia 
b. Your role on project 	Supervision of clinical care 
 
% Effort 70% 
  
c. Dates and costs of entire project 	7/1/86 - 6/30/93: $605,000 per year 
d. Dates and costs of current year 	7/1/92 - 6/30/93: $605,000 
e. Specific aims of project 	Provision of clinical care of sickle cell patients. 
f. Describe scientific and budgetary overlap 	None. 
g. Describe adjustments you will make if the present application is funded (budget, % effort, aims, etc.) 
None. 
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FOLLOW INSTRUCTIONS CAREFULLY. Incomplete, inaccurate, or ambiguous information about OTHER SUPPORT could lead to 
significant delays in the review and/or funding of the application. 
Other support is defined as all funds or resources, whether Federal, non•Federal, or institutional, available to the principal 
investigator/program director (and other key personnel named in the application) in direct support of their research endeavors through 
research or training grants, cooperative agreements, contracts, fellowships, gifts, prizes, and other means. 
Reporting requirements are: For each of the key personnel, describe (1) all currently active support and (2) all applications and proposals 
pending review or award, whether related to this application or not. If the support is part of a larger project, identify the principal 
investigator/program director and provide the data for the relevant subproject(s). If an individual has no active or pending support, check 
"None." Use continuation pages as needed to provide the required information in the format as shown below. Key personnel are 
defined as all individuals who participate in the scientific development or execution of the project. Key personnel typically will include 
all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or baccalaureate 
level provided they contribute in a substantive way to the scientific development or execution of the project. 
Name 	James R. Eckman 	Active 	X 	Pending 	  None 	  
Fulton-Dekalb 
a. Source and identifying no. 	H.H.S. Block Grant 	P I 	Hosp. Authority 
Title 	Cord Blood Screening for Hemoglobinopathies  
b. Your role on project 	Supervision of newborn screening program 	% Effort 	 5% 
c. Dates and costs of entire project 	10/1/85 - 9/30/93: $58,156 per year 
d. Dates and costs of current year 	10/1/92 - 9/30/93: $58,156  
e. Specific aims of project 	To provide newborn screening for sickle cell disease and other hemoglobinopthies for all 
newborn babies at Grady Memorial Hospital. 
f. Describe scientific and budgetary overlap 	None.  
g. Describe adjustments you will make if the present application is funded (budget, % effort, aims, etc.) 
None. 
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FOLLOW INSTRUCTIONS CAREFULLY. Incomplete, inaccurate, or ambiguous information about OTHER SUPPORT could lead to 
significant delays in the review and/or funding of the application. 
Other support is defined as all funds or resources, whether Federal, non•Federal, or institutional, available to the principal 
investigator/program director (and other key personnel named in the application) in direct support of their research endeavors through 
research or training grants, cooperative agreements, contracts, fellowships, gifts, prizes, and other means. 
Reporting requirements are: For each of the key personnel, describe (1) all currently active support and (2) all applications and proposals 
pending review or award, whether related to this application or not. If the support is part of a larger project, identify the principal 
investigator/program director and provide the data for the relevant subproject(s). If an individual has no active or pending support, check 
"None." Use continuation pages as needed to provide the required information in the format as shown below. Key personnel are 
defined as all individuals who participate in the scientific development or execution of the project. Key personnel typically will include 
all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or baccalaureate 
level provided they contribute in a substantive way to the scientific development or execution of the project. 
Name 	.lames R. Eckman 	Active 	X 	Pending 	  None 	  
a. Source and identifying no. 	NIH/NHLBI, 1 U01 45692-01 
 
P.I. 	Samuel Charache 
   
Title 	Hydroxyurea in Sickle Cell: Subcontract to Johns Hopkins 
  
b. Your role on project Local Principal Investigator 	% Effort 	5% 
 
 
   
c. Dates and costs of entire project 	5/1/91 - 4/30/96: $346,864 per year entire project 
d. Dates and costs of current year 	5/1/92 - 4/30/93: $67,370  
e. Specific aims of project This is a multi-center study of hydroxyurea in sickle cell anemia to determine whether or 
not treatment with hydroxyurea titrated to maximum tolerated doses will reduce to at least 50% the frequency 
of vaso-occlusive (painful) crisis. The secondary objectives are to establish the relationship of fetal hemoglobin 
levels and other patients or treatment characteristics to the occurrence of vaso-occlusive (painful) crises, and the 
effect of treatment on the quality of patients' lives.  
f. Describe scientific and budgetary overlap 	None.  
g. Describe adjustments you will make if the present application is funded (budget, % effort, aims, etc.) 
None. 
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FOLLOW INSTRUCTIONS CAREFULLY. Incomplete, inaccurate, or ambiguous information about OTHER SUPPORT could lead to 
significant delays in the review and/or funding of the application. 
Other support is defined as all funds or resources, whether Federal, non-Federal, or institutional, available to the principal 
investigator/program director (and other key personnel named in the application) in direct support of their research endeavors through 
research or training grants, cooperative agreements, contracts, fellowships, gifts, prizes, and other means. 
Reporting requirements are: For each of the key personnel, describe (1) all currently active support and (2) all applications and proposals 
pending review or award, whether related to this application or not. If the support is part of a larger project, identify the principal 
investigator/program director and provide the data for the relevant subproject(s). If an Individual has no active or pending support, check 
"None." Use continuation pages as needed to provide the required information in the format as shown below. Key personnel are 
defined as all individuals who participate in the scientific development or execution of the project. Key personnel typically will include 
all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or baccalaureate 
level provided they contribute in a substantive way to the scientific development or execution of the project. 
Name 	lames R Eckman 	Active 	X 	Pending 	  None 	  
a. Source and identifying no. National Cancer Institute 
 
P.I. Melvin Moore 
   
Title 	Grady Memorial Hospital Clinical Oncology Program 
b. Your role on project 	Co-Investigator  
 
% Effort 5% 
  
c. Dates and costs of entire project 	7/1/90 - 6/30/93: $24,959 per year 
d. Dates and costs of current year 	7/1/92 - 6/30/93: $24,959 
e. Specific aims of project 	To enroll minority patients in cancer chemotherapy trials. 
f. Describe scientific and budgetary overlap 	None. 
g. Describe adjustments you will make if the present application is funded (budget, % effort, aims, etc.) 
Effort is to be reduced to 0%. 
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Pending 	X 	None 	  
Fulton-Dekalb 
	 PI. Hosp. Authority 
  




       
Title 	Treatment of Sickle Cell Anemia 
b. Your role on project 	Supervision of clinical care 
 
% Effort 50% 
  
c. Dates and costs of entire project 	7/1/93 - 6/30/94: $575,000 per year 
d. Dates and costs of current year 	7/1/93 - 7/30/94: $575,000  
e. Specific aims of project 	Provision of clinical care of sickle cell patients.  
f. Describe scientific and budgetary overlap 	None.  
g. Describe adjustments you will make if the present application is funded (budget, % effort, aims, etc ) 
Dr. Eckman's previously proposed clinical effort and salary on this grant will be reduced to 50% because of the 
oreater effort devoted to research. 
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Other support is defined as all funds or resources, whether Federal, non•Federal, or institutional, available to the principal 
investigator/program director (and other key personnel named in the application) in direct support of their research endeavors through 
research or training grants, cooperative agreements, contracts, fellowships, gifts, prizes, and other means. 
Reporting requirements are: For each of the key personnel, describe (1) all currently active support and (2) all applications and proposals 
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Name 	James R. Eckman 
 
Active 	  Pending 	X 	None 	 
Fulton-Dekalb 
P.I. 	Hosp. Authority 
   
a. Source and identifying no. 	H.H.S. Block Grant 
 
    
Title 	Cord Blood Screening for Hemoglobinopathies 
   
b. Your role on project Supervision of newborn screening program 	% Effort 	 5% 
c. Dates and costs of entire project 	10/1/93 - 9/30/94: 558,156 per year 
d. Dates and costs of current year 10/1/93 - 9/30/94: $58,156 
 
e. Specific aims of project 
	To provide newborn screening for sickle cell disease and other hemoglobinopathies for all 
newborn babies at Grady Memorial Hospital. 
f. Describe scientific and budgetary overlap 	None.  
g. Describe adjustments you will make if the present application is funded (budget, °A effort, aims, etc.) 
None. 
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PRINCIPAL INVESTIGATOR OR PROGRAM DIRECTOR 
Timothy M. Wick, Ph.D.  
APPLICANT ORGANIZATION 
Georgia Institute of Technology  
TITLE OF PROJECT (Repeat title shown in item 1 on first page) 
Mechanism of Sickle Erythrocyte/Endotheli& 
(SEE INSTRUCTIONS) 
FROM 
1 July 1993 
PERIOD COVERED BY THIS REPORT  
THROUGH 
30 June 1994 
20horPnce 
1. Specific Aims 
The tendency for hemoglobin SS to polymerize at low oxygen tension is assumed to be the dominant 
factor in sickle cell pathology. Since morphological sickling is delayed after hemoglobin 
deoxygenation, factors which delay red cell microcirculatory transit are likely antecedents to 
microvascular occlusion, ischemic tissue damage, and pain episodes characteristic of sickle cell 
anemia. Our central hypothesis is that sickle erythrocyte adherence to microvascular endothelium 
delays erythrocyte microcirculatory transit. This partial obstruction allows for intracapillary red cell 
sickling leading to complete occlusion (1). Our data clearly indicate that plasma, red cell and 
endothelial cell factors as well as local hemodynamics all likely contribute to adherence and occlusion 
in vivo (2-7). Our specific aims for this project are to (i) characterize differences in sickle red blood 
cell adherence to phenotypically diverse endothelium (veins, arteries, microvessels); (ii) identify 
specific plasma factors, red cell membrane abnormalities, and endothelial ligands which promote 
sickle red blood cell (SRBC) adherence, and (iii) characterize the interpatient and intrapatient 
adherence mechanisms and degree of adherence during asymptomatic periods and pain episodes. The 
long-term goal of this research is to discover the mechanisms and extent of sickle red cell adherence to 
different vascular sites during pain episodes and asymptomatic periods. These studies will be 
invaluable to the development of effective anti-adhesion therapies to eliminate or reduce the ischemic 
tissue damage associated with blood vessel occlusion in sickle cell anemia. 
2. Studies and Results 
Methods 
Adherence of sickle red blood cells (SRBC) to cultured human umbilical vein (HUVEC) and 
microvascular (MEC) endothelial cells was quantified under dynamic flow conditions in vitro 
essentially as described in the original grant application (6). 
Thrombospondin-Mediated Sickle Red Cell Adherence to Microvascular Endothelium 
We have previously reported that thrombospondin (TSP), possibly released from activated sickle 
platelets in vivo, promotes sickle red cell adherence to MEC under physiological flow conditions (2). 
A main goal for this budget period was further elucidation of the mechanism of TSP-mediated 
adherence. TSP binds to CD36 and the vitronectin receptor on MEC (2). However, it is not known 
whether TSP receptors are expressed on SRBC. We (Figure 1 & ref. 3) and others (8) have recently 
demonstrated that sickle reticulocytes express CD36, a TSP receptor (9). Normal reticulocytes also 
express CD36, but to a much lesser degree (data not shown - see reference 25). As shown in Figure 2, 
preincubation of SRBC with anti-CD36 antibody quantitatively blocks TSP-mediated SRBC adherence 
to MEC. 
When either SRBC or MEC are incubated with TSP, TSP promotes SRBC adherence (Fig 3). 
However separate incubation of both the SRBC and MEC with TSP prior to a flow adhesion assay 
does not promosimultaneous occupation of TSP receptors on both the SRBC and MEC inhibits 
adherence. 
We have previously reported that antibodies to either the vitronectin receptor (a03) or CD36 
quantitatively inhibit TSP-mediated SRBC adherence to MEC (2). Considerable ongoing debate does 
not clarify whether both of these receptors are TSP receptors or whether CD36 and a v 133 are closely 
opposed such that antibody occupation of one receptor sterically inhibits TSP access to the other 
receptor (10-12). To address this issue, we have utilized the sextapeptide (CSVTCG) sequence that is 
the purported CD36-binding domain of TSP (13) and the RGD sequence that binds to integrin 
receptors (14) to investigate further the role of CD36 and VnR in TSP-mediated adherence. 
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Preincubation of either SRBC or MEC with CSVTCG also abolishes TSP-mediated adherence (Fig 4). 
Similarly, princubation of MEC with RGD abolished adherence (Fig 5). 
Fig 1: Sickle RBC express CD36, a TSP receptor. 
SRBC were labeled with both thiazole orange (FL1) and 
anti-CD36 antibody (FL2) and analyzed by fluorescence 
activated cell sorting (FACS) (24). The population of 
RBC in quadrant 2 represent 8% of the patients RBC 
that are CD36-expressing reticulocytes. 
Fig 2: Anti-CD36 antibody inhibits TSP-mediated 
adherence to MEC. Preincubation of either SRBC or 
MEC with OKM5 antibody inhibits SRBC adherence to 
a similar extent (shown in parentheses). Unbound 
antibody was washed away prior to the adherence 
assay. Data are mean±SEM for the number of 
experiments in this and all plots (except where 
indicated). 
6AEC treat morn 
Fig 3: TSP mediates adhesion of SRBC to TSP. 
Preincubation of either SRBC or MEC with TSP 
promotes SRBC adherence; incubation of both MEC 
and SRBC with TSP does not promote adherence. 
Fig 4: TSP-mediated SRBC adherence is blocked by 
the antagonist peptide CSVTCG. Incubation of either 
MEC of SRBC with CSVTCG peptide quantitatively 
inhibits SRBC adherence to MEC. 
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RGDS Tetrepeptide Inhibits TSP-Mediated 
SRBC Adherence to MEC 
Fig 5: Preincubation of MEC with RGDS peptide inhibits TSP-mediated SRBC adhesion to MEC 92%. 
Endothelial Stimulation  
Using monoclonal antibodies and fluorescence activates cell sorting (FACS) we have recently 
demonstrated that a subpopulation of young reticulocytes in sickle blood express the a401  (VLA-4) 
integrin receptor (Fig 6). Normal reticulocytes also express VLA-4, but to a lesser degree (data not 
shown). Sickle reticulocytes do not express the al, a2, a3, a5, a6, av, 132, 03 integrin receptors (Fig 
6). The ligand for a4131 is VCAM-1 (15) which is expressed by HUVEC (16) and MEC (17) after. 
stimulation with cytokines such as tumor necrosis factor (16,17). SRBC, but not NRBC, adhere to 
TNF-a stimulated HUVEC (Fig 7) and this adherence is inhibited greater than 70% by incubating 
SRBC with an anti-a4Pi antibody or the HUVEC with an anti-VCAM-1 antibody (Fig 8). TNF-a 
also induces VCAM-1 expression on MEC (17). In one experiment, SRBC also adhered to cytokine 
activated MEC via a a4r3i/VCAM-1 dependent adherence pathway (Fig 9) similar to that observed for 
HUVEC. 
Thiazole orange 
Fig 6: SRBC were labeled with thiazole orange (to identify reticulocytes) (FL1) and an anti-a4 or anti-n1 (FL2) 
antibody and analyzed by FACS as described in Fig 1. The cells stained positive for both cut and 01. 
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Fig 7: TNF-a stimulated HUVEC 
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Fig 8: SRBC adhere to cytokine stimulated HUVEC 
via a VLA-4NCAM-1 dependent mechanism. Anti-
VCAM-1 or anti-VLA-4 antibody inhibited SRBC 
adherence to TNF-a stimulated HUVEC by 80% and 
74%, respectively. Neither incubation of HUVEC with 
anti-ICAM-1 or SRBC with anti-glycophorin inhibited 
SRBC adherence. 
L 
Sickle Erythrocyte Stimulation 
VLA-4 is constitutively expressed on a subpopulation of sickle reticulocytes (Fig 6) and promotes 
adherence to activated HUVEC via VCAM-1 (Fig 7). Recent data suggest that 131 integrins, including 
VLA-4, can be stimulated to exhibit higher affinity for their ligands (e.g. activated) (18) by phorbol 
esters and other agonists. In order to test the hypothesis that erythrocyte activation elevates sickle cell 
adherence to endothelium, we stimulated SRBC with phorbol dibutyrate (PDBu) prior to the flow 
adherence assays. As seen in Figure 10, PDBu activated sickle, but not normal, RBC are more 
adherent to cultured endothelium as compared to unstimulated SRBC. These adherence assays were 
conducted in the absence of any adherence proteins and without endothelial stimulation. Thus, the 
phorbol ester induced SRBC adherence appears to be via a pathway not dependent upon exogenous 
proteins or endothelial cell activation. 
50  
Fig 9: Sickle RBC adhere to TNF-a stimulated MEC. 
MEC were activated with TNF, washed SRBC suspended 
in SFM (containing no adhesive proteins) were perfused 
over the monolayer and adherent sickle cells were 
enumerated as described in Figs 7&8. Adherence was 
partially blocked by anti-a413i antibody on SRBC or by 
anti-VCAM-1 antibody on the MEC. 




Fig 10: Phorbol ester stimulation of SRBC elevates 
SRBC adherence to HUVEC. SRBC suspended in SFM 
were pretreated with phorbol ester (PDBu) and adherence 
to unstimulated HUVEC was quantified. In some 
experiments, HUVEC were pretreated with anti-VCAM-1 
or SRBC were pretreated with anti-VLA-4. The percent 
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3. Significance 
Effect of Endothelial Cell Phenotype 
We have recently reported that SRBC adherence to microvas19). Notably, high molecular 
weight von Willebrand factor multimers promote adherence to HUVEC but not MEC (19). In contrast, 
autologous plasma promotes very high SRBC adherence to MEC, but only low levels of SRBC 
adherence to HUVEC (19). The MEC are likely predominately of capillary origin, whereas the 
HUVEC may closely mimic the post-capillary venule endothelium (19). Thus, these data indicate that 
multiple and different pathways exist for SRBC adherence - and that (for example) plasma-mediated 
• adherence in the capillaries and adherence to post-capillary venule endothelium via high molecular 
weight vWF possibly act in tandem to provide greater blood flow impediment in the microcirculation. 
	
CC 	Here we report of two additional adherence pathways; one mediated by TSP and its receptors 
▪ on SRBC (CD36) and microvascular endothelium (CD36 and a vi33) and the other mediated by SRBC 
VLA-4 (a.4[31) binding to VCAM-1 expressed on TNF-a stimulated endothelium. Recently, Sugihara, 
et al. (8) reported that TSP also mediates SRBC adherence to HUVEC via CD36 on the SRBC and 
• unidentified receptor(s) on HUVEC. However, an RGDS peptide inhibited TSP-mediated binding (8) 
indicating that HUVEC integrin receptors are involved in adherence. Thus, the mechanism of TSP 
3 	mediated SRBC adherence to MEC and HUVEC is apparently analogous. Similarly, the ct4131/VCAM- 
✓ 1 adherence is significant for both TNF-a. stimulated HUVEC (Fig 8) and MEC (Fig 9). Thus, these 
g 	two pathways supports adherence of SRBC to both large vessel and microvascular endothelium and 
may participate in adherence in vivo in both the capillaries and post-capillary venules. 
✓ Endothelial Cell Activation 
One of our most significant observations is that SRBC express the cLIN integrin receptor and 
adhere to TNF-a activated HUVEC and MEC. Cytokine levels are elevated in sickle patients during 
asymptomatic periods and during acute illness (20). It is possible, especially in light of our recent data 
(Figs 6-9), that cytokine production may induce endothelial cell VCAM-1 expression and SRBC 
adherence in vivo, leading to microvascular occlusion. These data suggest that anti-cytokine therapy, 
to inhibit VCAM-1 expression, may be an alternative therapeutic strategy to prevent, minimize, or 
reverse sickle cell adherence to vascular endothelium and the accompanying necrotic tissue damage. 
We will further explore this hypothesis by monitoring patient cytokine levels in order to attempt 
J 
▪ 
correlations between plasma cytokine level, in vitro endothelial adherence, and disease severity. 
Sickle Cell Activation 
The data of Figure 10 suggest that sickle red blood Cells can exhibit higher affinity for 
endothelial cell receptors when stimulated with agonists such as phorbol ester. These data suggest an 
intriguing hypothesis that the SRBC can become 'activated' in vivo, exhibit greater affinity for the 
) 	endothelium, and lead to increased endothelial adherence and vaso-occlusion in the absence of 
changes in plasma concentrations of adhesive proteins or endothelial cell activation. Since these 
C 	data are only preliminary, we do not know if the increased adherence is due solely to a4Pi 'activation' 
) as we originally hypothesized or if other receptors are involved under these stimulation conditions. 
• However, it is unlikely that PDBu is exerting its effect through endothelial cell activation since the 
• phorbol ester is incubated with the red cells and the red cells are washed prior to the adherence assay. 
• Obviously, we will continue to explore this hypothesis and preliminary data to further determine 
5 	whether an 'activation' state exists for SRBC. 
) 4. Plans 
In general, we do not anticipate significant deviation from the original proposal. However, the 
future work will be focused on the data of most promise in elucidation of the mechanisms of sickle red 
cell/endothelial cell adherence in vivo, in order to provide data that is of use to developing anti-
adhesion therapies. We will focus on identifying the plasma components responsible for sickle cell 
adherence and will identify which adhesion pathway or pathways are most prominent in the plasma 
milieu. Thus, we will investigate adherence when sickle red cells are suspended in autologous plasma 
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(as opposed to incubated with purified proteins) since this mimics the in vivo milieu. Also, we will 
continue to identify and characterize the sickle red cell membrane receptor(s) and their ligands on 
endothelial cells. 
The Role of Inte,grin Receptors in Plasma -Mediated SRBC Adherence 
We have characterized several adherence pathways involving integrin receptors, including: VCAM-
1/041 (Fig 8), TSP/ocv 133 (ref 2), high molecular weight vWF/integrin receptor (ref 7). Others have 
O shown that fibrinogen (21) and fibronectin (4) also promote SRBC, possibly through endothelial 
	
UJ 	integrin receptors (22). We hypothesize that adherence to integrin receptors (possibly mediated by a ▪ variety of proteins) accounts for a significant fraction of the adherence in vivo. We will test this 
• hypothesis by examining SRBC adherence when erythrocytes are suspended in autologous plasma. 
ri We will identify specific plasma factors which promote adherence, especially integrin receptor agonist 
proteins (e.g. TSP, vWF, fibrinogen, fibronectin). In parallel, we will investigate peptides based on the 
RGD motif (which competes with RGD-containing proteins for integrin receptors [23]) for their ability 
Z 	to inhibit plasma-mediated adherence. In general, these peptides are commercially available. These 
experiments will be of interest because the experimental system we utilize closely mimics the 
microvascular milieu in vivo. That is, our SRBC adhesion experiments will be performed in 
Z 	autologous plasma on human microvascular endothelium under shear conditions typical of that in the 
microcirculation. Successful identification of RGD-containing peptides that inhibit plasma-mediated 
• adherence could form the basis for anti-adhesion therapies for patients. 
CC 	"Activated' Sickle Red Cells  2 
The data of Figure 9 indicate that sickle red cell affinity for endothelial cell ligands can be E 	significantly increased after stimulation with phorbol ester. This suggests that the red cell may 
periodically exhibit greater adhesivity for the endothelium in vivo. We plan to further explore this 
hypothesis with the following experiments. The fact that VLA4 on the SRBC accounts for only 
approximately half of the adherence when SRBC are stimulated with PDBu, suggests that other 
endothelial receptors are involved. Thus, using our monoclonal antibodies to a variety of adhesion 
receptors (VCAM-1, ELAM-1, ICAM-1, CD36, GPIb, a v(3, etc.) we will determine whether the 
stimulated RBC adhere via a known SRBC adherence pathway. In addition, since we have not directly 
demonstrated that the a4131 positive RBC are the adherent RBC in response to phorbol ester we will 
Li 	test a:43i positive and a431 negative cells subfractions of RBC to establish whether a4131 on SRBC is 
5 involved in adherence. These subfractions will be generated by density gradient centrifugation (25) 
C 	(since most of the a4(31 positive cells are reticulocytes which have low density) or fluorescence 
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5. Human Subjects 
a. General Guidelines 
i. Proposed Use 
Patients with sickle-cell syndromes (HbSS, HbSC, HbS 13-thalassemia) not receiving anticoagulant 
therapy and without evidence of pregnancy, obvious infection, thromboembolic disease or liver disease 
will be eligible for this study. Patients will be studied once in pain crisis and twice during 
asymptomatic periods. An age and sex matched population of normal black individuals will serve as a 
control population. Approximately twenty patients and twenty control subjects, aged eighteen or 
older, will be studied annually. Ten milliliters of blood will be drawn by venipuncture for each 
experiment 
ii. Specimen Usage 
None of the data from the experiments will be used for diagnosis or treatment of specific 
individuals. 
iii. Patient Recruitment 
Patients from the Sickle Cell Center or the in-patient service at Grady Memorial Hospital, 
Atlanta, GA and hospital staff will be recruited by Dr. James R. Eckman. Subjects will agree to 
participate in this study by signing a consent form approved by Georgia Tech and Emory University 
School of Medicine IRBs. The consent form explains the nature of the study, the details of blood 
collection, risks associated with drawing blood, the availability of personnel to discuss the results of 
the study, the assurance of anonymity, and the ability to withdraw from the study at any time without 
penalty or loss of benefits. 
iv Potential Risks 
The risks of drawing blood are minimal and include slight pain, bruising, and infection at the 
site of puncture. No viable alternative for drawing human blood exists. 
v. Procedures to Minimize Risk 
Patient confidentiality will be ensured by assigning a code to each patient studied (SS1, AA1 
for sickle and normal donor, respectively) to be used when all data is reported. Blood will be drawn at 
Grady Hospital under the supervision of Dr. James R. Eckman, director of the Sickle Cell Clinic. Dr. 
Eckman will be available to answer questions and to arrange for emergency medical care if a medical 
problem develops during the course of this study. 
vi. Justification 
The risk of blood drawing is minimal compared to potential benefits of a better understanding 
of clotting abnormalities in sickle cell syndromes and their relationship to pain crisis. 
b. Gender and Minority Inclusions  
Study subjects will be patients diagnosed with sickle cell syndromes as defined above. These patients 
will primarily be of African descent, however no patients will be included or excluded on the basis of 
race. The study population will consist of approximately equal numbers of men and women. 
Exclusion criteria will be solely based on medical criteria as described above. Control subjects 
(volunteers without hemoglobinopathies) will be age, sex, and race-matched. These volunteers are 
recruited from the hospital staff at Grady Memorial Hospital in Atlanta. 
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6. Vertebrate Animals 
None. 
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Check the appropriate boxes and provide the information requested. Make this page the last page of the signed original of the application. 
1. ASSURANCES/CERTIFICATIONS 
The following assurances/certifications are made by checking the appropriate boxes and verified by the signature of the OFFICIAL SIGN-
ING FOR APPLICANT ORGANIZATION on the FACE PAGE of the application. Descriptions of individual assurances/certifications begin on 
page 9 of Specific Instructions. 
a. Human Subjects (Complete Item 7 on the Face Page) 
Full IRB Review 	Expedited Review 
Use of Human Subjects ❑ Change 	[xi No Change Since Previous Submission 
b. Vertebrate Animals (Complete Item 8 on the Face Page) 
Use of Vertebrate Animals ❑ Change ❑ No Change Since Previous Submission 
c. Inventions and Patents (Complete Item 11 on the Face Page) None 
d. Debarment and Suspension E No 	7 Yes (Attach explanation) 
e. Lobbying 
With Federal appropriated funds 	 a No 
With other than Federal appropriated funds 	a No 	❑ Yes 
(If "yes", see page 13, and attach Standard Form LLL, "Disclosure of Lobbying Activities," to the application behind the Checklist.) 
f. Delinquent Federal Debt 	2 No 	Yes (Attach explanation) 
	
g. Misconduct in Science (Form PHS 6315)   Filed n Not Filed 
If fired, date of Initial Assurance or latest Annual Report 	1/14/92  
h. Civil Rights i. Handicapped Individuals j. Sex Discrimination k. Age Discrimination 
Form HHS 441 Form HHS 641 Form HHS 639-A Form HHS 680 
C Filed FA Filed E Filed X 	Filed 
❑ Not Filed ❑ Not Filed I 	Not Filed ❑ Not Filed 
2. PROGRAM INCOME (See Instructions, Page 16) 
All applications must indicate (Yes or No) whether program income is anticipated during the period(s) for which grant support is 
requested. E No 	7 Yes. If "Yes" use the format below to reflect the amount and source(s) of anticipated program income. 
Budget Period 	 Anticipated Amount 	 Sou rce(s) 
3. INDIRECT COST 
Indicate the applicant organization's most recent indirect cost rate established with the appropriate DHHS Regional Office. or. in the case 
of forprofit organizations, the rate established with the appropriate PHS Agency Cost Advisory Office. Indirect costs will not be paid on 
foreign grants, construction grants, grants to Federal organizations and grants to individuals, and usually not on conference grants. Follow 
any additional instructions provided for Research Career Development Awards, Institutional National Research Service Awards. and 
specialized grant applications. 
❑ DHHS Agreement Dated' 	  ❑ No Indirect Costs Requested 
• No DHHS Agreement, but rates established with  Office of Naval Research Date 8/26/92  
CALCULATION 
Enter proposed budget period: 
Amount of base $  44,470 	x Rate applied  0.449 	% = Indirect costs $1 9 , 967  
Add to total direct costs from form page 2 and enter new total on Face Page, item 10b 
*Check appropriate box(es): 
❑ Salary and wage base 	 E3 Modified total direct costs base 	 111 Other base (Attach explanation) 
❑ Off-site, other special rate, or more than one rate involved (Attach explanation) 
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